References
- Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–60
- CASCADE. Collaboration.Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000; 355: 1158–9
- Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 2000; 356: 291–6
- Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. EuroSIDA study group. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 1663–71
- Bonnet F, Morlat P, Chêne G, Mercié P, Neau D, Malvy D, et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy. HIV Medicine 2002; 3: 195–9
- Cohen MH, French AL, Benning L, Kovacs A, Anastos K, Young M, et al. Causes of death among females with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med 2002; 113: 91–8
- Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. and the ‘Mortalité ’ study group. Causes of death in HIV-infected adults in the era of highly active antiretroviral therapy (HAART): the French survey ‘Mortalité 2000’. Int J Epidemiol 2005; 34: 121–30
- International Classification of Diseases (10th Revision). Geneva: World Health Organization, 1993.
- Hamers FF, Downs AM. The changing face of the HIV epidemic in western Europe: what are the implications for public health policies?. Lancet 2004; 364: 83–94
- Lewden C, Raffi F, Cuzin L, Cailleton V, Vilde JL, Chene G, et al. Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation. J Infect Dis 2002; 186: 710–4
- Rapiti E, Porta D, Forastiere F, Fusco D, Perucci CA. Socioeconomic status and survival of persons with AIDS before and after the introduction of highly active antiretroviral therapy. Lazio AIDS Surveillance Collaborative Group. Epidemiology 2000; 11: 496–501
- McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. AIDS 1999; 13: 1687–95
- Masur R, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons, 2002 Recommendations of the US Public HealthService and the Infectious Diseases Society of America. Ann Intern Med 2002; 137((Suppl))435–77
- Maladies opportunistes et morbidité liées au VIH. In:. Prise en charge des personnes infectées par le VIH. Recommendation du groupe d'experts. Rapport 2002. Paris: Médecine-Science Flammarion, 2002:163–96.